Testing insulin and blood sugar monitoring with pioglitazone
Treatments studied
Part of Cancer, Hormones & metabolism, Skin clinical trials.
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ER-positive, HER2-negative metastatic breast cancer with a PIK3CA mutation
- You are planning to start alpelisib and fulvestrant (for your cancer) soon
- You are age 18 to 85 and can do daily activities at a level the study considers OK (ECOG 0–2)
- You can understand the study and agree to sign informed consent
- You do not have major stomach or gut problems that could affect how alpelisib is absorbed
- Your diabetes, if present, must not be poorly controlled (HbA1c must be 8% or lower) and you should not be on insulin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug dapagliflozin (a pill that lowers blood sugar) to standard chemotherapy before breast cancer surgery can improve outcomes. It is for women with high insulin levels and a higher BMI who are about to start chemotherapy.
This Phase 2 trial tests whether a combination of medicines can shrink and control HER2-negative metaplastic breast cancer that cannot be removed with surgery (locally advanced) or has spread (metastatic). It may help people whose cancer has specific lab/pathology features, and it also checks safety and how well the treatment works in the body.
This trial tests a drug called everolimus in women with hormone receptor-positive metastatic breast cancer who have already tried alpelisib (a PI3K inhibitor) combined with hormone therapy. The goal is to see if this next treatment can help control cancer growth.
This study tests a single dose of a drug called alpelisib (a PI3K inhibitor) to see how it affects insulin and blood sugar in people who are either insulin sensitive or insulin resistant. The goal is to understand why some people become resistant to insulin, which may help find new treatments for diabetes and related conditions.
This Phase 2 study tests whether pioglitazone can reduce fatigue in people with certain types of breast cancer. You may be eligible if your cancer is estrogen- and progesterone-positive (ER+/PR+) and you plan surgery soon.
This trial tests a new drug, inavolisib, combined with two standard treatments (fulvestrant and palbociclib) for people with advanced breast cancer and type 2 diabetes. It aims to find out if this combination is safe and effective.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.